Advertisement – Charles Stanley mid banner
Advertisement: EBCam mid banner
Advertisement: Kao Data Centre mid banner
Mid banner advertisement: BDO
Barr Ellison Solicitors – commercial property
Advertisement: Mogrify mid banner
ARM Innovation Hub
Advertisement: Howard Group mid banner
Advertisement: RSM
Advertisement mid banner S-Tech 1
Advertisement: Simpsons Creative
Advertisement: Cambridge Network mid banner
Advertisement: CJBS mid banner
Advertisement: Hewitsons mid banner
8 June, 2021 - 15:16 By Tony Quested

Cambridge helps drive new cell and gene therapy technology

A consortium of more than 20 organisations, including innovation hothouse Cambridge Consultants, has been formed by the UK’s Cell and Gene Therapy Catapult to fast-track nextgen technology in the sector.

The consortium comprises pharmaceutical companies, technology providers, therapy developers and charities. It will assess the application and combination of multiple technologies for process analytics within the cell and gene therapy industry.

This consortium is the first of this scale, functional expertise and mission within the cell and gene therapy space, bringing together multiple industries to develop cell and gene therapy specific process analytical technologies (PAT). 

Development of industry specific PAT is fundamental to enable monitoring and control during the manufacturing process: reducing batch failures and manufacturing costs, allowing for accelerated progress towards commercialisation in this space.

Through this model of collaborative work, sharing of data from the research carried out, partners will accelerate their expertise in this area and gain industry specific knowledge to integrate and combine cell and gene therapy process analytical technologies into their offering. 

This PAT consortium will act as a catalyst in accelerating the development of the necessary knowledge and understanding at reduced cost and investment risk to each organisation.

Access to this knowledge will allow technology providers and manufacturers to develop lower cost and more robust manufacturing processes, accelerating development of advanced therapeutics.

Matthew Durdy, CEO at Cell and Gene Therapy Catapult said: “The industry needs to make a giant leap in terms of analytical capability and the dynamic use of information to control and improve processes, product and costs. The coming together of these leaders in the field is a very important first step towards achieving this.”

Nicholas Medcalf, deputy challenge director – medicines manufacturing for Innovate UK added: “By sharing knowledge and data, the consortium members will be able to reap potentially huge benefits that could lead to more efficient processes in this vital field. 

“The Cell and Gene Therapy Catapult – supported by Innovate UK – is demonstrating its fantastic convening power in harnessing these leading industry players for the greater good of UK enterprise and innovation.”

The organisations that have formed the process analytics consortium are: ABER Instruments; Anthony Nolan; BD; Bio-Techne; Cambridge Consultants; Cell and Gene Therapy Catapult; ChemoMetec; C-CIT Sensors; Cytiva; Eppendorf; GlaxoSmithKline (GSK); HORIBA; IMSPEX Diagnostics Ltd; Kaiser Optical Systems, an Endress+Hauser company; Lonza; Ocean Insight; Ori Biotech; Oxford Nanoimaging; Quantex; See-Through; TeloNostiX; Terumo Blood and Cell Technologies; Univercells Technologies.

Newsletter Subscription

Stay informed of the latest news and features